Result of AGM

Summary by AI ^BETAClose X

Coiled Therapeutics plc announced the results of its Annual General Meeting, where all resolutions passed except for resolution 5, which concerned the re-appointment of Pamela Grand Frank as a non-executive director, resulting in her directorship ceasing. The company reported that out of 426,791,322 ordinary shares in issue, resolutions 1 through 4 and 6 through 13 received overwhelming support, with votes for ranging from 99.9856% to 99.9999%. Resolution 5, however, saw only 3.9189% of votes in favour and 96.0811% against.

Disclaimer*

Coiled Therapeutics PLC

24 June 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Result of Annual General Meeting

Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX) announces the results of voting on the resolutions at its Annual General Meeting ("AGM") held today. A poll was held on each resolution and all resolutions except resolution 5 were passed by the required majority. The results of the poll vote can be found below:

Resolution	Votes for	% Votes Cast	Votes against	% Votes Cast	Total Votes	Votes withheld
Resolution 1 (Ordinary)	162,528,440	99.9999%	117	0.0001%	162,528,557	20
Resolution 2 (Ordinary)	162,511,994	99.9960%	6,563	0.0040%	162,518,557	10,020
Resolution 3 (Ordinary)	162,508,941	99.9955%	7,257	0.0045%	162,516,198	12,379
Resolution 4 (Ordinary)	162,524,346	99.9975%	4,061	0.0025%	162,528,407	170
Resolution 5 (Ordinary)	6,369,320	3.9189%	156,159,087	96.0811%	162,528,407	170
Resolution 6 (Ordinary)	162,524,346	99.9975%	4,061	0.0025%	162,528,407	170
Resolution 7 (Ordinary)	162,523,652	99.9971%	4,755	0.0029%	162,528,407	170
Resolution 8 (Ordinary)	162,524,346	99.9975%	4,061	0.0025%	162,528,407	170
Resolution 9 (Ordinary)	162,523,646	99.9971%	4,755	0.0029%	162,528,401	170
Resolution 10 (Ordinary)	162,524,496	99.9975%	4,061	0.0025%	162,528,557	20
Resolution 11 (Ordinary)	162,514,496	99.9975%	4,061	0.0025%	162,518,557	10,020
Resolution 12 (Ordinary)	162,514,745	99.9917%	13,455	0.0083%	162,528,200	377
Resolution 13 (Special)	162,504,683	99.9856%	23,483	0.0144%	162,528,166	405

Resolution 5 related to the re‑appointment of Pamela Grand Frank as a non‑executive director; as the resolution was not passed, Ms Frank has not been re‑appointed, and Ms Frank's directorship therefore ceased at the conclusion of the AGM.

As at 24 June 2026, there were 426,791,322 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and have not been included in the calculation of the proportion of votes for or against a resolution.

-Ends-

Enquiries:

Coiled Therapeutics plc

Sotirios Stergiopoulos (Chairman)

Sridhar Vempati (CEO)

Via Burson Buchanan

SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker)

David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Shard Capital Partners LLP (Joint Broker)

Damon Heath

CPS Capital Group Pty Ltd (Joint Broker)

Jason Peterson / David Valentino

+44 (0)20 4530 6926

+61 (0)8 9223 2222

Burson Buchanan (Public Relations)

Henry Harrison Topham / Jamie Hooper / Toto Berger

+44 (0)20 7466 5000

Harbor Access (US Investor Relations)

Matt Kelly / Jonathan Paterson

+1 475 477 9404

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate dose-expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END